Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
11 "Sang Cheul Oh"
Filter
Filter
Article category
Keywords
Publication year
Authors
Case Report
Case Report of Pulmonary Sarcoidosis Suspected to be Pulmonary Metastasis in a Patient with Breast Cancer
Hye Sook Kim, Suk-young Lee, Sang Cheul Oh, Chul Won Choi, Jun Suk Kim, Jae Hong Seo
Cancer Res Treat. 2014;46(3):317-321.   Published online July 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.3.317
AbstractAbstract PDFPubReaderePub
Standard endocrine therapy and chemotherapy can induce long-term remission in breast cancer patients; however, breast cancer can recur at any site. Pulmonary nodules with lymphadenopathy in advanced cancer patients are likely to be assumed as metastases. A 44-year-old woman with a history of breast cancer was presented to our institution with abnormal findings on 18-fluorodeoxyglucose positron emission tomography imaging, which suggested lung metastasis. She had previously been diagnosed with breast cancer (T1N2M0, Stage IIIa, intraductal carcinoma, triple negative cancer). Histological analysis of the mediastinal lymph node biopsy demonstrated sarcoidosis, showing a chronic, non-caseating, granulomatous inflammation. Our case highlights the need for non-malignant diagnoses in those with prior malignancies, and the need for histological evaluations in the event of first recurrence following potentially curative therapy.

Citations

Citations to this article as recorded by  
  • Endobronchial ultrasound-guided transbronchial needle aspiration facilitating diagnosis of sarcoidosis in a breast cancer patient with multiple lymphadenopathy: a case report
    Yuka Oride, Yumiko Koi, Tatsunari Sasada, Keiko Kajitani, Masahiro Ohara, Tomohiro Kondo, Yutaka Daimaru, Shingo Kawamura
    Journal of Medical Case Reports.2022;[Epub]     CrossRef
  • Sarcoidosis or metastatic rectal cancer? Diligent diagnosis for optimal therapeutic management
    Tanya Odisho, Sonal Kaushik, An King Ang
    Current Problems in Cancer: Case Reports.2022; 8: 100187.     CrossRef
  • Sarcoid-Like Lesions Mimicking Pulmonary Metastasis: A Case Series and Review of the Literature
    Hendrik Eggers, Marcus Krüger, Katharina Stange, Danny Jonigk, Christian Biancosino, Thomas Rodt, Thomas Fühner, Tim Murray, Viktor Grünwald, Philipp Ivanyi
    Oncology Research and Treatment.2019; 42(7-8): 382.     CrossRef
  • Concurrent Diagnoses of Cutaneous Sarcoidosis and Recurrent Metastatic Breast Cancer: More than a Coincidental Occurrence?
    Jacqueline Deen, Nick Mellick, Laura Wheller
    Case Reports in Dermatological Medicine.2018; 2018: 1.     CrossRef
  • 18F-FLUOROESTRADIOL PET/CT IN DIFFERENTIAL DIAGNOSIS OF LUNG LESIONS IN BREAST CANCER PATIENTS: CASE REPORTS
    N. В. Vikhrova, A. A. Odzharova, M. В. Dolgushin, D. I. Nevzorov
    Siberian journal of oncology.2018; 17(5): 111.     CrossRef
  • Coexistence of sarcoidosis and metastatic lesions: A diagnostic and therapeutic dilemma (Review)
    Christoph Spiekermann, Meike Kuhlencord, Sebastian Huss, Claudia Rudack, Daniel Wei�
    Oncology Letters.2017;[Epub]     CrossRef
  • Sarcoidosis Presenting with Multiple Lung Parenchymal Nodules
    Hyung-Jun Kim, Jimyung Park, Jee Min Kim, Ye Jin Lee, Hye-Rin Kang, Chang-Hoon Lee
    The Ewha Medical Journal.2016; 39(2): 61.     CrossRef
  • Systemic sarcoidosis mimicking malignant metastatic disease
    Irena Hammen, David Lee Sherson, Jesper Roemhild Davidsen
    European Clinical Respiratory Journal.2015; 2(1): 26761.     CrossRef
  • Baohuoside I Suppresses Invasion of Cervical and Breast Cancer Cells through the Downregulation of CXCR4 Chemokine Receptor Expression
    Buyun Kim, Byoungduck Park
    Biochemistry.2014; 53(48): 7562.     CrossRef
  • 15,575 View
  • 109 Download
  • 13 Web of Science
  • 9 Crossref
Close layer
Original Articles
A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer
Jong Gwon Choi, Jae Hong Seo, Sang Cheul Oh, Chul Won Choi, Jun Suk Kim
Cancer Res Treat. 2012;44(2):127-132.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.127
AbstractAbstract PDFPubReaderePub
PURPOSE
The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer.
MATERIALS AND METHODS
Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2 of oral capecitabine twice a day on days 1-21 of a 28-day cycle.
RESULTS
Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95% CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI, 2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%), and hand-foot syndrome (10%).
CONCLUSION
Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.

Citations

Citations to this article as recorded by  
  • Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials
    Abhinav Shenoy, Amar Yousif, Muhammad Delwar Hussain
    Cancers.2025; 17(8): 1319.     CrossRef
  • Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma
    Kimmen Quan, Philip Sutera, Karen Xu, Mark E. Bernard, Steven A. Burton, Rodney E. Wegner, Herbert Zeh, Nathan Bahary, Ronald Stoller, Dwight E. Heron
    Practical Radiation Oncology.2018; 8(2): 95.     CrossRef
  • A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
    Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Ho Gak Kim, Myung Hwan Noh, Sang Hyub Lee, Yong-Tae Kim, Hyo Jung Kim, Chang Duck Kim, Dong Ki Lee, Kwang Bum Cho, Chang Min Cho, Jong Ho Moon, Dong Uk Kim, Dae Hwan Kang, Youn
    Medicine.2017; 96(1): e5702.     CrossRef
  • Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
    P. Jiménez-Fonseca, M. P. Solis, M. Garrido, L. Faez, D. Rodriguez, A. L. Ruiz, M. L. Sanchez Lorenzo, E. Uriol, M. D. Menendez, J. M. Viéitez
    Clinical and Translational Oncology.2015; 17(5): 384.     CrossRef
  • Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
    Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, Marniza Saad, Adlinda Alip, Wan Zamaniah Wan Ishak
    Asian Pacific Journal of Cancer Prevention.2015; 16(4): 1449.     CrossRef
  • An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
    Chao Tu, Feng Zheng, Jin-Yu Wang, Yuan-Yuan Li, Ke-Qing Qian
    Asian Pacific Journal of Cancer Prevention.2015; 16(14): 5681.     CrossRef
  • Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer
    Ibrahim Vedat Bayoglu, Umut Varol, Ibrahim Yildiz, Ugur Muslu, Ahmet Alacacioglu, Yuksel Kucukzeybek, Murat Akyol, Lutfiye Demir, Ahmet Dirican, Suna Cokmert, Yasar Yildiz, Bulent Karabulut, Ruchan Uslu, Mustafa Oktay Tarhan
    Asian Pacific Journal of Cancer Prevention.2014; 15(17): 7119.     CrossRef
  • Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
    Jae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Cho
    Cancer Research and Treatment.2014; 47(2): 266.     CrossRef
  • Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
    Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
    PLoS ONE.2014; 9(8): e104346.     CrossRef
  • Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance
    Chunfang Xu, Airong Wu, Hua Zhu, Huaying Fang, Lele Xu, Jianxin Ye, Jiaqing Shen
    Biomedicine & Pharmacotherapy.2013; 67(2): 133.     CrossRef
  • 11,874 View
  • 64 Download
  • 10 Crossref
Close layer
Chemotherapy in Patients Older than or Equal to 75 Years with Advanced Non-small Cell Lung Cancer
Seung Tae Kim, Kyong Hwa Park, Sang Cheul Oh, Jae Hong Seo, Jun Suk Kim, Yeul Hong Kim, Sang Won Shin
Cancer Res Treat. 2012;44(1):37-42.   Published online March 31, 2012
DOI: https://doi.org/10.4143/crt.2012.44.1.37
AbstractAbstract PDFPubReaderePub
PURPOSE
As the number of elderly patients diagnosed with non-small cell lung carcinoma (NSCLC) increases, the number of these patients receiving chemotherapy also increases. However, limited data exists regarding the use of chemotherapy in advanced NSCLC patients who are 75 years of age or older.
MATERIALS AND METHODS
Between May 2002 and October 2008, data for 48 advanced NSCLC patients who were 75 years of age or older who had been treated with chemotherapy were retrospectively analyzed.
RESULTS
The median age of study participants at the time of first line chemotherapy was 76 years (range, 75 to 87 years) and their median Charlson comorbidity index was 2 (range, 1 to 4). Of the total 48 patients, 43 patients (90%) were treated by platinum-based doublet as a first line chemotherapy regimen. Median progression free survival for first line chemotherapy was 5.7 months (95% confidence interval [CI], 4.93 to 6.47 months) with an overall response rate of 33.3%. After first line chemotherapy, only 14 of the 48 patients (29.2%) received second line chemotherapy. The median overall survival (OS) for these patients was 8.2 months (95% CI, 4.44 to 11.96 months). Multivariate analysis results indicated that female gender and having received second-line or more chemotherapy were independent prognostic factors for increased OS for all 48 patients. Charlson Index was not a significant independent prognostic factor for survival. There were 9 treatment related deaths due to infectious causes (18.8%).
CONCLUSION
Patients 75 years of age or older with advanced NSCLC may obtain clinical benefit from the administration of platinum-based doublet or single agent chemotherapy. However, oncologists must consider the aspect of safety in relation to the clinical benefits when managing this patient group.

Citations

Citations to this article as recorded by  
  • A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
    Hee Kyung Ahn, Minkyu Jung, Sun Jin Sym, Dong Bok Shin, Shin Myung Kang, Sun Young Kyung, Jeong-Woong Park, Sung Hwan Jeong, Eun Kyung Cho
    Cancer Chemotherapy and Pharmacology.2014; 74(2): 277.     CrossRef
  • Management of Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Single-Center Experience
    M. Früh, H. Besrour, S. Gillessen, M. Joerger, F. Hitz, A. Savidan, T. Cerny, S. Ess
    Chemotherapy.2013; 59(1): 42.     CrossRef
  • 11,117 View
  • 53 Download
  • 2 Crossref
Close layer
Clinical Factors Related to Suspected Second Primary Lung Cancer Development in Patients with Head and Neck Cancer
Eui Bae Kim, Yong Park, Seh Jong Park, Dae Sik Kim, Jee Won Kim, Hee Yun Seo, Hwa Jung Sung, In Keun Choi, Kyong Hwa Park, Sang Cheul Oh, Chul Won Choi, Byung Soo Kim, Yeul Hong Kim, Jun Suk Kim, Sang Won Shin, Chul Yong Kim, Kwang-Yoon Jung
Cancer Res Treat. 2008;40(4):178-183.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.178
AbstractAbstract PDFPubReaderePub
Purpose

The rate of second primary lung cancer development for patients with head and neck cancer (HNC) has been noted. The aim of our study was to evaluate the incidence and clinical features of suspected second primary lung cancer that developed in patients with primary HNC.

Materials and Methods

We conducted a retrospective study of 469 patients who were newly diagnosed with HNC at the Korea University Medical Center between January 2000 and December 2006.

Results

A total of 469 patients were included (389 men and 80 women). Eighteen patients (3.8%) had suspected second primary lung cancers. Statistically significant clinical variables for lung cancer development included the origin site for the primary HNC (oro-hypopharynx and larynx) (p=0.048), abnormal chest x-ray findings (p=0.027) and the histological HNC type (squamous cell carcinoma) (p=0.032). When the second primary lung cancers were combined with HNCs, the adjusted overall survival of patients with a second primary lung cancer was 16 months (p<0.001).

Conclusions

Considering the relative risk factors for a second primary lung cancer developing in patients with HNC, advanced diagnostic tools, such as chest CT or PET CT scan, should be applied for the early detection of a second primary lung cancer.

Citations

Citations to this article as recorded by  
  • Long-Term Survival in Metachronous Primary Malignancies: Stage III Nasopharyngeal Cancer and Stage IV Non-Small-Cell Lung Cancer
    Gabriela Rahnea-Nita, Alexandru Nechifor, Mihai-Teodor Georgescu, Dorel Firescu, Adrian-Cornel Maier, Radu-Valeriu Toma, Valentin Titus Grigorean, Liliana-Florina Andronache, Roxana-Andreea Rahnea-Nita, Ionut Simion Coman, Laura-Florentina Rebegea
    Journal of Clinical Medicine.2025; 14(10): 3299.     CrossRef
  • African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer
    Yusra F. Shao, Seongho Kim, John D. Cramer, Dina Farhat, Jeffrey Hotaling, Syed Naweed Raza, George Yoo, Ho‐sheng Lin, Harold Kim, Ammar Sukari, Misako Nagasaka
    Head & Neck.2022; 44(10): 2069.     CrossRef
  • Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?
    Tarun Jain, Guman Singh, Sumit Goyal, Ajay Yadav, Dinesh Yadav, Nitin Khunteta, Hemant Malhotra
    World Journal of Nuclear Medicine.2021; 20(02): 164.     CrossRef
  • Modern Radiology in the Management of Head and Neck Cancer
    G.J.C. Burkill, R.M. Evans, V.V. Raman, S.E.J. Connor
    Clinical Oncology.2016; 28(7): 440.     CrossRef
  • Synchronous Squamous Cell Carcinoma and Chronic Lymphocytic Leukemia of the Palate
    Pablo Rosado, Soledad Fernández, Luis Junquera, Juan Carlos De Vicente
    Journal of Craniofacial Surgery.2011; 22(1): 348.     CrossRef
  • 11,437 View
  • 72 Download
  • 5 Crossref
Close layer
The Bone Morphogenesis Protein-2 (BMP-2) is Associated with Progression to Metastatic Disease in Gastric Cancer
Yong Park, Jee Won Kim, Dae Sik Kim, Eui Bae Kim, Se Jong Park, Jin Yong Park, Woo Suk Choi, Jong Gyu Song, Hee Yun Seo, Sang Cheul Oh, Byung Soo Kim, Jong Jae Park, Yeul Hong Kim, Jun Suk Kim
Cancer Res Treat. 2008;40(3):127-132.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.127
AbstractAbstract PDFPubReaderePub
Purpose

Bone Morphogenetic Proteins (BMPs) are members of the TGF-β superfamily and it has been demonstrated that BMPs enhance migration, invasion and metastasis. The purpose of this study was to identify the association between the serum BMP-2 level and the progression status of gastric cancer.

Materials and Methods

Fifty-five patients with metastatic gastric cancer (metastatic disease group), six patients with early gastric cancer without lymph node metastasis (the EGC group), and ten healthy control subjects were enrolled in this study. The serum BMP-2 level was quantified by use of a commercially available ELISA kit. In EGC group patients and patients with metastatic disease, whole blood was obtained before endoscopic mucosal resection and before the commencement of a scheduled cycle of systemic chemotherapy, respectively.

Results

No significant difference in the mean serum BMP-2 levels was observed between the control subjects and the EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p=1.0). However, the metastatic disease group patients had a significantly higher level of serum BMP (179.61 pg/ml) than the control subjects and EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p<0.0001). Moreover, the mean serum BMP-2 level from patients with a bone metastasis was significantly higher than the mean serum BMP-2 level from patients without a bone metastasis (204.73 pg/ml versus 173.33 pg/ml, p=0.021).

Conclusions

BMP-2 seems to have a role in progression to metastatic disease in gastric cancer, especially in the late stage of tumorigenesis, including invasion and metastasis. BMP-2 may facilitate bone metastasis in gastric cancer. To confirm these findings, further studies are required with tissue specimens and the use of a cancer cell line.

Citations

Citations to this article as recorded by  
  • Novel Biomarkers in Evaluating Cardiac Function in Patients on Hemodialysis—A Pilot Prospective Observational Cohort Study
    Lazar Chisavu, Viviana Mihaela Ivan, Adelina Mihaescu, Flavia Chisavu, Oana Schiller, Luciana Marc, Flaviu Bob, Adalbert Schiller
    Diagnostics.2024; 14(6): 664.     CrossRef
  • Duality of bone morphogenetic proteins in cancer: A comprehensive analysis
    Tanu Sharma, Anmol Kapoor, Chandi C. Mandal
    Journal of Cellular Physiology.2022; 237(8): 3127.     CrossRef
  • BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer
    Zilu Chen, Liyue Yuan, Xiaopeng Li, Junhui Yu, Zhengshui Xu
    Cell Cycle.2022; 21(21): 2298.     CrossRef
  • Emerging Roles for Browning of White Adipose Tissue in Prostate Cancer Malignant Behaviour
    Alejandro Álvarez-Artime, Belén García-Soler, Rosa María Sainz, Juan Carlos Mayo
    International Journal of Molecular Sciences.2021; 22(11): 5560.     CrossRef
  • Magnesium ions regulate mesenchymal stem cells population and osteogenic differentiation: A fuzzy agent-based modeling approach
    Jalil Nourisa, Berit Zeller-Plumhoff, Heike Helmholz, Bérengère Luthringer-Feyerabend, Vladimir Ivannikov, Regine Willumeit-Römer
    Computational and Structural Biotechnology Journal.2021; 19: 4110.     CrossRef
  • BMP Signaling in Development, Stem Cells, and Diseases of the Gastrointestinal Tract
    Yongchun Zhang, Jianwen Que
    Annual Review of Physiology.2020; 82(1): 251.     CrossRef
  • Relaxin enhances bone regeneration with BMP‐2‐loaded hydroxyapatite microspheres
    Sahitya Injamuri, Mohamed N. Rahaman, Youqu Shen, Yue‐Wern Huang
    Journal of Biomedical Materials Research Part A.2020; 108(5): 1231.     CrossRef
  • Annatto-Derived Tocotrienol Promotes Mineralization of MC3T3-E1 Cells by Enhancing BMP-2 Protein Expression via Inhibiting RhoA Activation and HMG-CoA Reductase Gene Expression


    Wan Nuraini Wan Hasan, Kok-Yong Chin, Norzana Abd Ghafar, Ima Nirwana Soelaiman
    Drug Design, Development and Therapy.2020; Volume 14: 969.     CrossRef
  • Detection of circulating BMP5 as a risk factor for Barrett’s esophagus
    Ana C. P. Correia, Silvia Calpe, Nahid Mostafavi, Sanne Johanna Maria Hoefnagel, Maria del Carmen Sancho-Serra, Patricia S. de Koning, Kausilia K. Krishnadath
    Scientific Reports.2020;[Epub]     CrossRef
  • The Dual Role of Bone Morphogenetic Proteins in Cancer
    Duc-Hiep Bach, Hyen Joo Park, Sang Kook Lee
    Molecular Therapy - Oncolytics.2018; 8: 1.     CrossRef
  • Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
    Tobias Sinnberg, Heike Niessner, Mitch P. Levesque, Christoph Dettweiler, Claus Garbe, Christian Busch
    Biology Open.2018;[Epub]     CrossRef
  • Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis
    Bum Sik Tae, Seok Cho, Hyun Cheol Kim, Cheol Hwan Kim, Seok Ho Kang, Jeong Gu Lee, Je Jong Kim, Hong Seok Park, Jun Cheon, Mi Mi Oh, Sung Gu Kang
    Scientific Reports.2018;[Epub]     CrossRef
  • Computational model of mesenchymal migration in 3D under chemotaxis
    F. O. Ribeiro, M. J. Gómez-Benito, J. Folgado, P. R. Fernandes, J. M. García-Aznar
    Computer Methods in Biomechanics and Biomedical Engineering.2017; 20(1): 59.     CrossRef
  • Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy
    Haijun Tian, Jie Zhao, Elsa J. Brochmann, Jeffrey C. Wang, Samuel S. Murray
    Cytokine & Growth Factor Reviews.2017; 34: 73.     CrossRef
  • BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells
    Min Hu, Facai Cui, Fengzhen Liu, Jinlin Wang, Xiaoxia Wei, Yi Li
    International Journal of Oncology.2017; 50(1): 193.     CrossRef
  • Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis
    Jian Sun, Xuan Liu, Hong Gao, Long Zhang, Qing Ji, Ziyuan Wang, Lihong Zhou, Yan Wang, Hua Sui, Zhongze Fan, Qi Li
    Oncotarget.2017; 8(7): 11489.     CrossRef
  • BMP10 inhibited the growth and migration of gastric cancer cells
    Haiming Lei, Jian Wang, Peihua Lu, Xinghua Si, Koulan Han, Tingyan Ruan, Junjie Lu
    Tumor Biology.2016; 37(3): 3025.     CrossRef
  • How does the pathophysiological context influence delivery of bone growth factors?
    Xiaohua Yu, Darilis Suárez-González, Andrew S. Khalil, William L. Murphy
    Advanced Drug Delivery Reviews.2015; 84: 68.     CrossRef
  • Inactivation of the Phosphatidylinositol 3‐Kinase/Akt Pathway is Involved in BMP9‐mediated Tumor‐suppressive Effects in Gastric Cancer Cells
    Liang Duan, Liwei Ye, Rui Wu, Haiyan Wang, Xueru Li, Huan Li, Shimei Yuan, He Zha, Hui Sun, Yunyuan Zhang, Xian Chen, Yan Zhang, Lan Zhou
    Journal of Cellular Biochemistry.2015; 116(6): 1080.     CrossRef
  • Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2
    Yun-Jung Choi, Patrick N. Ingram, Kun Yang, Lan Coffman, Mangala Iyengar, Shoumei Bai, Dafydd G. Thomas, Euisik Yoon, Ronald J. Buckanovich
    Proceedings of the National Academy of Sciences.2015;[Epub]     CrossRef
  • Association Between BMP-2 and Carcinogenicity
    Branko Skovrlj, Steven M. Koehler, Paul A. Anderson, Sheeraz A. Qureshi, Andrew C. Hecht, James C. Iatridis, Samuel K. Cho
    SPINE.2015; 40(23): 1862.     CrossRef
  • In silico Mechano-Chemical Model of Bone Healing for the Regeneration of Critical Defects: The Effect of BMP-2
    Frederico O. Ribeiro, María José Gómez-Benito, João Folgado, Paulo R. Fernandes, José Manuel García-Aznar, Masaya Yamamoto
    PLOS ONE.2015; 10(6): e0127722.     CrossRef
  • Comparative transcriptome analysis between metastatic and non-metastatic gastric cancer reveals potential biomarkers
    DAN FENG, XIAOFEI YE, ZHENXIN ZHU, ZIRAN WEI, QINGPING CAI, YAJIE WANG
    Molecular Medicine Reports.2015; 11(1): 386.     CrossRef
  • Gastric stem cells and gastric cancer stem cells
    Myoung-Eun Han, Sae-Ock Oh
    Anatomy & Cell Biology.2013; 46(1): 8.     CrossRef
  • Cancer stem cells: the ‘heartbeat’ of gastric cancer
    Guihua Xu, Jie Shen, Xiaohui Ou Yang, Masakiyo Sasahara, Xiulan Su
    Journal of Gastroenterology.2013; 48(7): 781.     CrossRef
  • Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients
    Zheng-Hua Fei, Cheng-Yun Yao, Xiao-Lei Yang, Xin-En Huang, Sheng-Lin Ma
    Asian Pacific Journal of Cancer Prevention.2013; 14(9): 5293.     CrossRef
  • P‐glycoprotein (ABCB1) inhibited network of mitochondrion transport along microtubule and BMP signal‐induced cell shape in chimpanzee left cerebrum by systems‐theoretical analysis
    Hong Lin, Lin Wang, Minghu Jiang, Juxiang Huang, Lianxiu Qi
    Cell Biochemistry and Function.2012; 30(7): 582.     CrossRef
  • Bone–vasculature interactions in the mandible: Is bone an angiogenic tissue?
    E.M. Dietrich, K. Antoniades
    Medical Hypotheses.2012; 79(5): 582.     CrossRef
  • Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients
    Elísio Costa, Joana Coimbra, Cristina Catarino, Sandra Ribeiro, Flávio Reis, Henrique Nascimento, João Fernandes, Vasco Miranda, Maria do Sameiro Faria, Luís Belo, Alice Santos-Silva
    Renal Failure.2012; 34(10): 1355.     CrossRef
  • Bone Morphogenetic Protein-4-induced Epithelial-Mesenchymal Transition and Invasiveness Through Smad1-mediated Signal Pathway in Squamous Cell Carcinoma of the Head and Neck
    Ting Xu, Chang-yun Yu, Jin-jie Sun, Yong Liu, Xing-wei Wang, Lei-ming Pi, Yong-quan Tian, Xin Zhang
    Archives of Medical Research.2011; 42(2): 128.     CrossRef
  • Bone Morphogenetic Protein-2 and -4 Play Tumor Suppressive Roles in Human Diffuse-Type Gastric Carcinoma
    Yo-taro Shirai, Shogo Ehata, Masakazu Yashiro, Kazuyoshi Yanagihara, Kosei Hirakawa, Kohei Miyazono
    The American Journal of Pathology.2011; 179(6): 2920.     CrossRef
  • Metastatic function of BMP-2 in gastric cancer cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression
    Myoung Hee Kang, Sang Cheul Oh, Hyun Joo Lee, Han Na Kang, Jung Lim Kim, Jun Suk Kim, Young A. Yoo
    Experimental Cell Research.2011; 317(12): 1746.     CrossRef
  • Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma
    Ulrike Maegdefrau, Stephanie Arndt, Georgi Kivorski, Claus Hellerbrand, Anja-Katrin Bosserhoff
    Laboratory Investigation.2011; 91(11): 1615.     CrossRef
  • Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood IgA nephropathy
    JIN-SOON SUH, WON-HO HAHN, JONG SEOK LEE, HAE JEONG PARK, MI-JA KIM, SUNG WOOK KANG, JOO-HO CHUNG, BYOUNG-SOO CHO
    Experimental and Therapeutic Medicine.2011; 2(2): 337.     CrossRef
  • Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression
    Yong Park, Myoung Hee Kang, Hee Yeon Seo, Joong Min Park, Chul Won Choi, Yeul Hong Kim, In Sun Kim, Jun Suk Kim, Sang Cheul Oh
    Medical Oncology.2010; 27(4): 1192.     CrossRef
  • The Yin and Yang of bone morphogenetic proteins in cancer
    Ashok Singh, Rebecca J. Morris
    Cytokine & Growth Factor Reviews.2010; 21(4): 299.     CrossRef
  • BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
    Myoung Hee Kang, Jun Suk Kim, Ji Eun Seo, Sang Cheul Oh, Young A. Yoo
    Experimental Cell Research.2010; 316(1): 24.     CrossRef
  • 12,437 View
  • 76 Download
  • 37 Crossref
Close layer
Microsatellite Alterations in Serum DNA of Lung Cancer Patients
Sang Cheul Oh, Young Do Yoo, So Young Yoon, Seok Jin Kim, Jae Hong Seo, Kwang Taek Kim, Sang Won Shin, Yo Han Kim, Yeul Hong Kim, Jun Suk Kim
Cancer Res Treat. 2003;35(4):289-293.   Published online August 31, 2003
DOI: https://doi.org/10.4143/crt.2003.35.4.289
AbstractAbstract PDF
No abstract available.
  • 4,370 View
  • 19 Download
Close layer
Pilot Study of Heptaplatin, UFT-E and Leucovorin in Advanced Gastric Carcinoma
Sang Cheul Oh, So Young Yoon, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho, Jun Suk Kim
Cancer Res Treat. 2003;35(2):117-122.   Published online April 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.2.117
AbstractAbstract PDF
PURPOSE
Heptaplatin (SKI-2053R, Sunpla ), a new platinum analogue which has a better toxicity profile than cisplatin, has been used with 5-fluorouracil (5-FU) continuous infusion for the treatment of advanced gastric carcinoma. However, continuous 5-FU infusion had a inconvenience to administration. The aim of this study was to evaluate the efficacy and toxicity of heptaplatin, UFT-E and leucovorin combination chemotherapy in advanced gastric cancer.
MATERIALS AND METHODS
A total of 22 patients was enrolled in this study at Kyung Hee University and Korea University from September 1999 to May 2001. Heptaplatin 400 mg/m2 was given as intravenous infusion for 1 hour at day 1. Oral UFT-E 360 mg/m2 and leucovorin 45 mg/day were administered for 21 consecutive days followed by a 7-day drug free interval. This schedule was repeated every 4 weeks. RESULTS: The 22 enrolled patients received 81 courses of chemotherapy and the median number of course per patient was three with a range of one to six. Five of 21 patients achieved partial responses (23.8%; 95% confidence interval, 5.6% to 42%) without complete response. Out of the 5 responding patients, three had unresectable perigastric lymph-nodes, one patient had a ovarian metastasis, and one patient had a peritoneal metastasis respectively. Main toxicities were neutropenia and nausea/vomiting. Grade 3 and 4 neutropenia were observed in 4 patients (18%) and grade 3 nausea/vomiting were observed in 5 patients (22.7%). The median time to progression was 4 months (range, 0.5 to 13 months), and median survival duration was 7.5 months (range, 2.0 to 14 months). Median response duration was 5.0 months (range, 1.5 to 10 months). CONCLUSION: A combination chemotherapy of heptaplatin, UFT-E and leucovorin has a comparable efficacy with those of previously reported heptaplatin and intravenous regimen of 5-FU and controllable toxicity in advanced gastric carcinoma. Further study with large patient population is warranted to determine the usefulness of this regimen.

Citations

Citations to this article as recorded by  
  • Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters
    Xi Hu, Fangyuan Li, Nabila Noor, Daishun Ling
    Science Bulletin.2017; 62(8): 589.     CrossRef
  • The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
    Dalton Transactions.2010; 39(35): 8113.     CrossRef
  • A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer
    Won Sup Lee, Gyeong-Won Lee, Hwal Woong Kim, Ok-Jae Lee, Young-Joon Lee, Gyung Hyuck Ko, Jong-Seok Lee, Joung Soon Jang, Woo Song Ha
    Cancer Research and Treatment.2005; 37(4): 208.     CrossRef
  • Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study
    Myung-Ju Ahn, Ho-Suck Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon
    Cancer Research and Treatment.2004; 36(3): 182.     CrossRef
  • 4,668 View
  • 23 Download
  • 4 Crossref
Close layer
Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer
Seok Jin Kim, Hwa Jung Sung, Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Kwang Taek Kim, Young Ho Choi, Jun Suk Kim
Cancer Res Treat. 2002;34(6):421-425.   Published online December 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.6.421
AbstractAbstract PDF
PURPOSE
The combination of cisplatin and etoposide has been a common first line regimen for the treatment of small cell lung cancer (SCLC). The schedule dependence, and equal efficacy, of the oral and intravenous dosing of etoposide has led to prolonged administration of oral etoposide, which is known to produce an encouraging response in SCLC. To improve the efficacy of the cisplatin/etoposide combination, we administered oral etoposide, with added ifosfamide, which had significant single agent activity against SCLC. We conducted this study to evaluate the efficacy and toxicity of the cisplatin, ifosfamide and oral etoposide (PIE) combination in patients with extensive small cell lung cancer.
MATERIALS AND METHODS
Twenty-five patients with histologically confirmed extensive small cell lung cancer were enrolled into this study between January 2000 and May 2002. They were treated with, cisplatin at 20 mg/ m2/day, ifosfamide 1.5 g/m2/day, with mesna (all given intravenously on Days 1~3), and oral etoposide 50 mg/m2 on days 4~17. This cycle was repeated every 4 weeks for up to 6 cycles. We evaluated the corresponding disease responses and toxicities.
RESULTS
The patients' characteristics were as follows: median age 65 years (32~75), 19 males and 6 females. The performance stati were ECOG 0 in 3 patients, ECOG 1 in 12 and ECOG 2 in 10. Sixteen patients had a partial response, 2 had a stable disease and 4 had a progressive disease. Thus, the overall objective response rate was 72.7% (95% CI: 49.6~88.4%), with a median response duration of 7 months (95% CI: 3.5~10.5 months). Myelosuppression was the major observed toxicity. Grades III and IV neutropenia were observed in 42 (46.1%) of the 91 cycles. Significant non-hematological toxicities (>or=Grade III) were uncommon, with the exception of nausea and vomiting.
CONCLUSION
The response rate to the combination of cisplatin, ifosfamide and oral etoposide was similar to that of other combination chemotherapy studies in patients with extensive disease small cell lung cancer. The toxicity of the regimen was considered acceptable.
  • 4,667 View
  • 26 Download
Close layer
Pirarubicin, UFT, Leucovorin Chemotherapy in Non-embolizable and Transcatheter Arterial Chemoembolization-Failed Hepatocellular Carcinoma Patients; A Phase II Clinical Study
Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Jong Eun Yeon, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Kwan Soo Byun, Jun Suk Kim, Chang Hong Lee
Cancer Res Treat. 2002;34(4):280-283.   Published online August 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.4.280
AbstractAbstract PDF
Hepatocellular carcinomas are one of the most common malignancies in the world. However, no effective therapeutic modality has been proven to prolong the survival of patients in an inoperable stage. The purpose of this study was to determine the response rate and the toxicities of a combination of pirarubicin, UFT and leucovorin in patients with non-embolizable hepatocellular carcinomas, or who had progressed during their transcatheter arterial chemoembolization treatment.
MATERIALS AND METHODS
Of 23 patients with a hepatocellular carcinoma, 11 had progressed during a transcatheter arterial chemoembolization, with the other 12 being transcatheter arterial chemoembolization-naive. All the patients were treated with pirarubicin (70 mg/m2 i.v., day 1), UFT (350 mg/m2 P.O., day 1~21), and leucovorin (25 mg/m2 P.O., day 1~21).
RESULTS
Twenty patients were able to be evaluated, with a partial response being achieved in four, giving an overall response rate of 20% (95% confidence interval, 7~44%). The median overall survival time was 6 months, and the median survival time of the transcatheter arterial chemoembolization-naive patients was significantly longer than that of those treated by transcatheter arterial chemoembolization (p=0.012). The most significant dose-limiting toxicity was leucopenia and thrombocytopenia.
CONCLUSION
The combination of pirarubicin, UFT and leucovorin therapies showed marginal antitumor activity and significant toxicity in patients with non-embolizable or failed transcatheter arterial chemoembolization hepatocellular carcinomas.
  • 4,373 View
  • 17 Download
Close layer
Stability of Cisplatin and Etoposide in Normal Solution
Sang Cheul Oh, Young Mi Kim, Young Inn You, Song Ja Jo, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim
J Korean Cancer Assoc. 1997;29(4):700-705.
AbstractAbstract PDF
PURPOSE
The cisplatin and etoposide had been reported to be an effective anti-tumor drug for small cell lung cancer, ovarian cancer, breast cancer and so on. The aim of this study was to evaluate the stability of cisplatin and etoposide in aqueous solution.
MATERIALS AND METHODS
Cisplatin 200 microgram/ml was prepared in 0.9% sodium chloride and stored in either glass bottle or polyvinyl chloride (pvc) bag and protected from light or exposed to fluorescent light. Etoposide solution was prepared in 0.9% sodium chloride, and contained in glass bottle. Precipitating concentration was achieved using 200 microgram/ml, 400microgram/ml, 600 microgram/ml, and 1000 microgram/ml of etoposide solution. Samples were stored at room temperature and visually inspected and assayed for etoposide and cisplatin content by high-performance liquid chromatography after 15 minutes, 2, 4, 8, 12, 16 and 24 hours of storage.
RESULT
1) Cisplatin concentration decreased less than 10% from initial concentration for 24 hours of storage, both in glass bottle and pvc bag. Stability of cisplatin 200 microgram/ml in both container were not different. and Condition of light exposure did not have significant effect on stability of cisplatin 200 microgram/ml in glass bottle. 2) The etoposide 200 microgram/ml was not precipitated and stable for 24 hours, but we could find the precipitates of etoposide with the concentration of 400 microgram/ml or higher for 24 hours.
CONCLUSION
Cisplatin 200 microgram/ml and etoposide 200 microgram/ml in 0.9% sodium chloride were stable at room temperature under room fluorescent light for 24 hours.
  • 4,210 View
  • 69 Download
Close layer
A Case of Head and Neck Cancer Diagnosed In a Systemic Lupus Erythematosus Patient
Sang Cheul Oh, Suk Jin Kim, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Gwan Gyu Song, Jun Suk Kim
J Korean Cancer Assoc. 1997;29(1):171-175.
AbstractAbstract PDF
Systemic lupus erythematosus (SLE) is one of the connective diseases characterized by altered immunity and has a high incidence of cancers, such as malignant lymphoma, leukemia, breast cancer and cervical cancer. Lymphadenopathy is one of the clinical findings of SLE. But it is also seen in cancer metastasis. Therefore, if the SLE patient has lymphadenopathies from cancer metastasis it is very difficult to make a differential diagnosis between the manifestation of SLE and that of cancer metastasis. In Korea, there is no report on SLE associated with lymphadenopathies from cancer metastasis. This is the first report of a case of SLE with a cervical lympadenopathy that comes from the metastasis of head and neck squamous cell carcinoma.
  • 2,966 View
  • 25 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP